Enzyme replacement therapy

Wednesday 8 June 2022
Country

Netherlands

An enzyme replacement therapy for two types of Niemann-Pick disease is being recommended for marketing by the European Medicines Agency. If formally approved by the European Commission, the drug, Xenpozyme (olipudase alfa), would be the first specific treatment for the disease, which is a rare genetic metabolic disorder.